coiaward2010

Our survey on complementary medicine in CML recently published in the „Journal of Cancer Research and Clinical Oncology“

cam-titleThe Survey on the Worldwide CML Advocates Network regarding Complementary and Alternative Medicine (CAM) which was conducted in collaboration with the CML Advocates Network was published in the March edition of the "Journal of Cancer Research and Clinical Oncology" (see Pubmed). 53 leaders of CML patients advocacy groups from 35 countries responded to the survey. Thank you all for your valuable contribution!

poster of the survey is now available for download, and click on "Read more" to read the abstract.

 


 

 

Survey on the worldwide Chronic Myeloid Leukemia Advocates Network regarding complementary and alternative medicine

Thomas Elsner, Ralph Muecke, Oliver Micke, Franz J. Prott, Karsten Muenstedt, Anita Waldmann, Jan Geissler & Jutta Huebner

Journal of Cancer Research and Clinical Oncology, DOI 10.1007/s00432-013-1414-4

Abstract

Purpose: Many cancer patients use complementary and alternative medicine (CAM). However, data in hematological cancers are lacking on which types of CAM are being used, what information sources on CAM patients use and to what extent CAM is being addressed in the consultation with the hematologist.

Methods: We developed a standardized questionnaire on CAM which was provided online to the representatives of the worldwide Chronic Myeloid Leukemia Advocates Network.

Results: A total of 53 leaders of patients’ advocacy groups for chronic myeloid leukemia (CML) patients from 35 countries responded to the survey. In almost all countries, CAM is important for CML patients and is widely used in addition to conventional leukemia treatment. Mostly, patients have to pay by themselves. General practitioners, herbalists, healers and naturopaths are the main sources for CAM treatments. Information on CAM is derived most frequently from the Internet, and family and friends, but rarely provided by the oncologist. Disclosure of CAM use to the oncologist is low, but increases if oncologists offer CAM.

Conclusions:  In spite of very different health care systems, the features of CAM usage are similar in the different countries. We suggest extending the cooperation of selfhelp and scientists in order to provide training of oncologists on CAM and quality-controlled, evidence-based information on CAM on the Internet both for patients as well as health professionals as a promising strategy to increase safe use of CAM in patients with CML.

 

For registered members

Download the article


 
   
 

Please donate!

Please donate!

LogIn

Tweet Feed

CdnCMLNetwork
Scary cancer stats drive policy - and apathy? cmlnetwork.ca/do-scary-cance… @picardonhealth @cancersociety @UHN_News @cmlnet @CBCToronto

Retweeted Wednesday, 28 June 2017

EHA_Hematology
Thanks to all who attended #EHA22! Hope you had a great time as we did. See you next year at #EHA23 in Stockholm! #hematology

Retweeted Sunday, 25 June 2017

HeretoHelpMDS
Day 1 #eha22: patient advocacy professionals. C.Chomienne opening our meeting for our very eager newbies + wise vet… twitter.com/i/web/status/8…

Retweeted Sunday, 25 June 2017